Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Another look at vascular access news and research in 2024
Healio has compiled a list of the most-read vascular access nephrology news in 2024.
Patients with antibody-associated vasculitis can recover kidney function
An early diagnosis of antibody-associated vasculitis may be important to long-term kidney function, study data show, as even mild forms of kidney involvement can affect prognosis.
Growing armamentarium means ‘we have options’ for ANCA-associated vasculitis
An growing therapeutic armamentarium for antineutrophil cytoplasmic antibody-associated vasculitis — including avacopan and azathioprine — is providing rheumatologists with an increasingly robust array of options, according to a presenter.
Amgen to obtain ChemoCentryx for nearly $4 billion
Amgen announced that it will acquire ChemoCentryx Inc. for $52 per share in cash, amounting to nearly $4 billion in cash, in the fourth quarter of 2022.
Top in rheumatology: Tavneos vs. prednisone, biology of MIS-C
In a randomized, double-blind, controlled study, Tavneos showed a significantly greater increase in glomerular filtration rate compared with prednisone in patients with renal disease associated with anti-neutrophil cytoplasmic antibody vasculitis.